title: Therapeutic utilities of fibroblast growth factor 19.
abstract: BACKGROUND
  Diabetes and associated metabolic conditions have reached pandemic proportions worldwide and there is a clear unmet medical need for new therapies that are both effective and safe. FGF19 is a distinctive member of the FGF family that functions as an endocrine hormone.
  
  
  METHODS
  An up-to-date report on the exciting findings related to the involvement of FGF19 in the regulation of glucose, bile acid metabolism and energy expenditure. The role of FGF receptors in these different activities. The therapeutic potential of FGF19 and the engineering opportunities for removing undesirable mitogenic activity.
  
  
  CONCLUSIONS
  The ability of FGF19 to regulate bile acid homeostasis, gallbladder filling and tumor development and its potent ability to normalize glucose, lipid and energy homeostasis have made it a potential therapeutic target for the treatment of patients with gallstones, cancer and metabolic diseases, among others. Its potential utility as a novel therapeutic for both type 1 and type 2 diabetes is of particular interest. The ability to separate the undesired mitogenic activity from its potent metabolic activities has opened new opportunities for the development of potential therapeutic molecules based on FGF19 in treating various conditions associated with metabolic syndrome.
authors.affiliation: Amgen, Inc., 1120 Veterans Blvd, South San Francisco, CA 94080, USA.
authors.forename: Xinle
authors.initials: X
authors.lastname: Wu
authors.forename: Yang
authors.initials: Y
authors.lastname: Li
mesh_terms: D000818:Animals; D001647:Bile Acids and Salts / Q000378:metabolism; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy / Q000503:physiopathology; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy / Q000503:physiopathology; D016503:Drug Delivery Systems; D015195:Drug Design; D005346:Fibroblast Growth Factors / Q000378:metabolism* / Q000627:therapeutic use; D005947:Glucose / Q000378:metabolism; D006801:Humans; D024821:Metabolic Syndrome / Q000188:drug therapy / Q000503:physiopathology; D015202:Protein Engineering; D017468:Receptors, Fibroblast Growth Factor / Q000378:metabolism*
chemical_list: D001647:Bile Acids and Salts; C117476:FGF19 protein, human; D017468:Receptors, Fibroblast Growth Factor; D005346:Fibroblast Growth Factors; D005947:Glucose